Overview
The clinical importance of using MR techniques for monitoring tumor
response to anticancer therapy is rapidly growing. Recent advances in
the design of therapeutic agents and methods have made it possible to
combine cancer therapy with MR imaging as well as other imaging
modalities to enable imaging responses.Target Audience
Clinicians and M.D. & Ph.D. researchers who will benefit from tool and
techniques for noninvasively measuring tumor response to therapy and
combining therapy with MR imaging for theranostic MRI.
Educational Objectives
Upon completion of this course, participants should be able to:
- Assess the advantages and
disadvantages of different MR techniques for measuring tumor
response to therapy;
- Evaluate the added value of
different MR approaches to monitor lung, rectal, gynocological and
pediatric brain tumours; and
- Understand the options for imaging tumours and the differences
in protocols associated with different anatomical tumour locations.
|
13:30
|
Quantitative Imaging of Metastatic Kidney Cancer 
Laure Fournier1, Alexandre Bellucci1,
Yann Vano2, Daniel Balvay3,
Stephane Oudard2, and Charles Andre Cuenod1
1Radiology, Hopital Europeen Georges
Pompidou, Paris, France, 2Medical
Oncology, Hopital Europeen Georges Pompidou, Paris,
France, 3Team
2, INSERM U470, Paris, France
Current treatment of metastatic renal cell carcinoma
relies on anti-angiogenic drugs, used successively, to
prolong patient survival. Functional imaging accompanied
anti-angiogenic drug development by helping elicit
biological mechanisms, and developing biomarkers of
tumour response. Remaining challenges include
understanding drug escape mechanisms and toxicities of
anti-angiogenic drugs, as well as accompanying clinical
trials using new immunotherapies.
|
14:00
|
MR Imaging biomarkers in assessing response to therapy of
rectal cancer
Andrea Laghi
Neoadjuvant chemo-radiotherapy (CRT) has become the
standard treatment for locally advanced rectal cancer.
In order to define the best therapeutic strategy
following CRT, either extended surgery (Total Mesorectal
Excision, TME), low-invasive transanal endoscopic
microsurgery (TEM) or wait-and-watch strategy, an
accurate assessment of tumor response to therapy is
mandatory. Currently, MR is the modality of choice in
assessing response to therapy. However, conventional
morphological imaging methods are not accurate enough,
particularly in evaluating complete response.
Quantitative imaging biomarkers are under evaluation,
with some of them showing preliminary interesting
results, namely diffusion-weighted imaging, texture
analysis and perfusion MR.
|
14:30
|
A Practical Approach to MRI of Female Pelvic Masses
Katja Pinker-Domenig1
1Dept. of Biomedical Imaging and Image-guided
Therapy, Medical University of Vienna, Vienna, Austria
Female pelvic masses comprise a broad spectrum of benign
and malignant tumors and conditions that often pose a
diagnostic challenge. A systematic evaluation that
integrates the clinical and surgical history and
multiparametric magnetic resonance imaging (MRI) to
identify the anatomic origin, morphologic features, and
tissue composition of a female pelvic mass helps to
establish a short, meaningful differential diagnosis or,
often, even a definitive diagnosis. This presentation
aims to review the standard female pelvic based on the
indications and provide a practical approach to MRI of
female pelvic masses.
|
15:00
|
Pediatric Brain
Benjamin Cohen1
1NYU Langone Medical Center
In conjunction with conventional sequences,
advanced/quantitative MR imaging techniques can refine
differential diagnostic considerations, suggest tumor
grade, propose targets for stereotactic biopsy, and
monitor response to therapy for pediatric brain
neoplasms.
|
15:30
|
Adjournment & Meet the
Teachers |
|